Dupilumab generated roughly $14 billion in 2025 sales by blocking IL-4/IL-13 signaling at the receptor level — and Kymera is now running two parallel Phase 2b trials betting that degrading STAT6, the transcription factor those cytokines activate, produces meaningfully deeper and broader suppression of Type 2 inflammation than any injectable biologic can reach. That is the actual hypothesis under test in BROADEN2 and BREADTH, and it is a more consequential clinical question than the trial designs alone suggest.
BROADEN2 enrolls approximately 200 patients aged 12 to 75 with moderate-to-severe atopic dermatitis across 16 weeks, with EASI percent change from baseline as the primary endpoint. BREADTH runs 264 adults with moderate-to-severe eosinophilic asthma over 12 weeks, anchored on pre-bronchodilator FEV1 change. Both are randomized, double-blind, placebo-controlled, dose-ranging studies — three doses of KT-621 each — and enrollment in both is active now. The Phase 1b data presented at AAD in March showed deep STAT6 protein degradation in blood and lesional skin simultaneously, with reductions in Type 2 inflammatory biomarkers and clinical signal across AD and comorbid conditions. Clean six-to-nine-month GLP toxicology in rat and NHP, with no adverse findings at any dose, removes one of the more realistic failure modes for a first-in-class degrader at this stage.
The asthma Fast Track designation — added to the existing AD Fast Track — matters less for timeline and more as a signal that FDA views the mechanism as addressing an unmet need distinct from existing biologics. That framing is important because KT-621’s differentiation story depends entirely on oral bioavailability plus transcription-factor-level degradation producing responses in patients who either cannot access or have failed anti-IL-4Rα therapy. The Phase 2b dose-ranging design will also generate the receptor occupancy and PK/PD relationship data needed to justify a Phase 3 dose before that decision has to be made.
The single number to track as BROADEN2 progresses toward mid-2027 readout: EASI-75 response rate in the highest KT-621 dose arm relative to the placebo rate in that same trial. Dupilumab hit roughly 38% EASI-75 versus 9% placebo in its pivotal AD study; if KT-621 cannot clear a comparable threshold orally, the entire STAT6-degradation-over-receptor-blockade argument collapses regardless of biomarker data.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
